Trials / Terminated
TerminatedNCT04633187
Effects of EDP-938 in Hematopoietic Cell Transplant Recipients Infected With Respiratory Syncytial Virus of the Upper Respiratory Tract
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Effects of EDP-938 in Hematopoietic Cell Transplant Recipients With Acute Respiratory Syncytial Virus Infection of the Upper Respiratory Tract
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- Enanta Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 16 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This was a Phase 2b, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy and safety of EDP-938 in HCT recipients with acute RSV infection and symptoms of URTI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDP-938 | EDP-938 800mg Dose adjustments were made for subjects taking azole antifungals. |
| DRUG | Placebo | Subjects took EDP-938 matching placebo tablets once a day orally for 21 days |
Timeline
- Start date
- 2021-07-07
- Primary completion
- 2023-05-31
- Completion
- 2023-05-31
- First posted
- 2020-11-18
- Last updated
- 2024-08-22
- Results posted
- 2024-08-22
Locations
64 sites across 19 countries: United States, Argentina, Belgium, Brazil, Canada, China, Colombia, France, Greece, Israel, Italy, Mexico, Poland, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04633187. Inclusion in this directory is not an endorsement.